Advancing Design Strategy of PROTACs for Cancer Therapy
MedComm · 2025-07 · 6 (7)
DOI: 10.1002/mco2.70258 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 25.06.2025. Verfasst von Hang Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 219 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs) have emerged as a groundbreaking class of anticancer therapeutics. These bifunctional molecules harness the endogenous ubiquitin–proteasome system to facilitate the degradation of targeted proteins of interest (POIs). Notably, the clinical translation of PROTACs has gained substantial momentum, with many PROTAC candidates targeting various cancers currently undergoing clinical trials (Phase I–III). However, the rational design of high‐efficacy PROTAC compounds remains a significant challenge. In this review, we presented a comprehensive overview of POI ligands, E3 ligands, and their interconnected linkers in PROTAC design, including their generation, structural optimization, and contribution to degradation efficiency and selectivity. Particularly, we analyzed the distinct preferences of various types of POI ligands (small molecule, nucleic acid, and peptide) toward specific targets. Furthermore, we emphasized the significant role of artificial intelligence technology in PROTAC design, including POI/E3 ligands discovery and linkers generation or optimization. We also summarized the applications and challenges of PROTACs in cancer therapy. Finally, we discussed the future development of PROTAC by combining multidisciplinary technologies and novel modalities for cancer therapy. Overall, this review aims to provide valuable insights for advancing PROTAC design strategies for cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chinese Medicine Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China.
- Law Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine Hong Kong Baptist University Hong Kong SAR China.
- Increasepharm & Hong Kong Baptist University Joint Centre for Nucleic Acid Drug Discovery Hong Kong, Science Park, New Territories Hong Kong SAR China.
ORCID-Profile: Yuan Ma
Zitieren
APA
Luo, H., Tian, Y., Abdullah, R., Zhang, B., Ma, Y., & Zhang, G. (2025). Advancing Design Strategy of PROTACs for Cancer Therapy. MedComm, 6(7). https://doi.org/10.1002/mco2.70258
Vancouver
Luo H, Tian Y, Abdullah R, Zhang B, Ma Y, Zhang G. Advancing Design Strategy of PROTACs for Cancer Therapy. MedComm. 2025;6(7). doi:10.1002/mco2.70258
BibTeX
@article{Luo2025,
author = {Luo, Hang and Tian, Yuan and Abdullah, Razack and Zhang, Baoting and Ma, Yuan and Zhang, Ge},
title = {Advancing Design Strategy of PROTACs for Cancer Therapy},
journal = {MedComm},
year = {2025},
volume = {6},
number = {7},
doi = {10.1002/mco2.70258}
}
EUVIMED